Internal Medicine Department, Rheumatology and Immunology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Pathology department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Inflammopharmacology. 2022 Dec;30(6):2181-2195. doi: 10.1007/s10787-022-01025-8. Epub 2022 Jul 13.
Rheumatoid arthritis (RA) is a known debilitating autoimmune disease. Immune-suppressants that are used for disease treatment have serious side effects, therefore, trivalent chromium (Cr (III)); which has shown evidence of its influences on some inflammatory pathways and cytokines; was used in this study for the first time to be assessed for its therapeutic effect in RA rat model and was compared to prednisolone in a trial to find a treatment with lesser side effects.
Adult male albino rats were randomly divided into four groups: normal, untreated RA, prednisolone treated RA (1.25 mg/kg/day) and Cr (III) treated RA groups (80 μg/kg/day), induction of RA was done by subcutaneous complete Freund adjuvant injection. Study duration was 4 weeks throughout which arthritis scoring and weight measurement were pursued. Histopathological examination and immunohistochemical FOXP3 assessment were done for joint biopsies. Serum inflammatory markers (interleukin 17, interleukin 10, CRP) and synovial erosive arthritis marker (Cathepsin G) were measured. HDL and non-HDL cholesterol were estimated as well.
Cr (III) treatment showed marked clinical and histopathological improvement, also astonishing anti-inflammatory effects (increase in FOXP3 expression and interleukin 10, with decrease in interleukin 17, CRP and synovial Cathepsin G) to the extent that Cr (III) effects on inflammation abolishment were comparable to that of prednisolone and even better at some aspects. Moreover, Cr (III) was protective from side effects, i.e., weight gain and dyslipidemia that were seen with prednisolone treatment.
Cr (III) is promising in treating RA and it lacks some side effects of accustomed immune-modulatory agents including prednisolone. Further experimental studies and clinical trials should be held to see the efficacy of Cr (III) in different doses and to assess its long term side effects when used for rheumatoid arthritis and other autoimmune diseases treatment.
类风湿性关节炎(RA)是一种已知的使人衰弱的自身免疫性疾病。用于疾病治疗的免疫抑制剂有严重的副作用,因此,三价铬(Cr(III));已经证明它对一些炎症途径和细胞因子有影响;首次在本研究中用于评估其在 RA 大鼠模型中的治疗效果,并与泼尼松龙进行试验,以寻找一种副作用较小的治疗方法。
成年雄性白化大鼠随机分为四组:正常组、未治疗 RA 组、泼尼松龙治疗 RA 组(1.25mg/kg/天)和 Cr(III)治疗 RA 组(80μg/kg/天),通过皮下注射完全弗氏佐剂诱导 RA。研究持续 4 周,在此期间进行关节炎评分和体重测量。对关节活检进行组织病理学检查和免疫组化 FOXP3 评估。测量血清炎症标志物(白细胞介素 17、白细胞介素 10、CRP)和滑膜侵蚀性关节炎标志物(组织蛋白酶 G)。还估计了高密度脂蛋白和非高密度脂蛋白胆固醇。
Cr(III)治疗显示出明显的临床和组织病理学改善,也具有惊人的抗炎作用(FOXP3 表达和白细胞介素 10 增加,白细胞介素 17、CRP 和滑膜组织蛋白酶 G 减少),以至于 Cr(III)对炎症的消除作用与泼尼松龙相当,在某些方面甚至更好。此外,Cr(III)对泼尼松龙治疗引起的体重增加和血脂异常等副作用有保护作用。
Cr(III)在治疗 RA 方面很有前途,它缺乏一些习惯免疫调节剂的副作用,包括泼尼松龙。应该进行进一步的实验研究和临床试验,以评估不同剂量的 Cr(III)的疗效,并评估其在治疗类风湿性关节炎和其他自身免疫性疾病时的长期副作用。